🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

63 results for “inhalation” Clear

  1. A phase I study investigating the local tolerability and pharmacokinetics of isoniazid (INH) inhalation by wet nebulization in patients with tuberculosis

    Disc Medicine

    Tuberculosis

    phase 1 other active

    1 trial

  2. A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])

    Lacuna Pharma Pty Ltd

    Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

    phase 1 other active

    1 trial

  3. Carbon Monoxide inhalation

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 1 small molecule terminated

    1 trial

  4. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  5. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma and chronic obstructive pulmonary disease (COPD).

    phase 1 other active

    1 trial

  6. Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  7. Human interferon alfa 1b inhalation solution

    United Therapeutics Europe Ltd

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  8. Treprostinil Inhalation Powder

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    1 trial

  9. Epinephrine (0.125 mg/inhalation)

    Amphastar France Pharmaceuticals

    Pharmacokinetics

    approved other completed

    1 trial

  10. Fostair 200 microgram/6 microgram per actuation pressurised inhalation solution, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    Chiesi Farmaceutici S.p.A

    Asthma

    approved small molecule active

    1 trial

  11. LABA/LAMA or Placebo inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis Adult

    approved small molecule active

    1 trial

  12. Test preparation：Methylcholine chloroacetate for inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Asthma

    approved small molecule completed

    1 trial

  13. Test preparation：Methylcholine chloroacetate for inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy People

    approved small molecule completed

    1 trial

  14. The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

    Pierre Fabre Australia Pty Ltd

    Chronic Obstructive Pulmonary Disease

    approved other active

    1 trial

  15. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources